These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8371515)

  • 1. Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. I. Inactivation of enzyme protein.
    Ito Y; Nakamura S; Onoda Y; Sugawara Y; Takaiti O
    Jpn J Pharmacol; 1993 Jun; 62(2):169-74. PubMed ID: 8371515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal protective effects of ecabet sodium: pepsin inhibition and interaction with mucus.
    Pearson JP; Roberts NB
    Clin Sci (Lond); 2001 Apr; 100(4):411-7. PubMed ID: 11256980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. II. Interaction with substrate protein.
    Ito Y; Onoda Y; Nakamura S; Tagawa K; Fukushima T; Sugawara Y; Takaiti O
    Jpn J Pharmacol; 1993 Jun; 62(2):175-81. PubMed ID: 8371516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ecabet sodium prevents esophageal lesions induced by the reflux of gastric juice in rats.
    Okuyama K; Saito N; Kume E; Noto T; Nagasaki M
    Inflammopharmacology; 2007 Apr; 15(2):90-4. PubMed ID: 17450449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ecabet sodium, a novel locally-acting anti-ulcer agent, protects the integrity of the gastric mucosal gel layer from pepsin-induced disruption in the rat.
    Kinoshita M; Endo M; Yasoshima A; Saito N; Yamasaki K; Chishima S; Narita H
    Aliment Pharmacol Ther; 1999 May; 13(5):687-94. PubMed ID: 10233194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of anti-urease action by the anti-ulcer drug ecabet sodium.
    Ito Y; Hongo A; Kinoshita M; Tamaki H
    Biol Pharm Bull; 1995 Jun; 18(6):850-3. PubMed ID: 7550119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pepsins, peptic activity, and peptic inhibitors.
    Samloff IM
    J Clin Gastroenterol; 1981; 3(Suppl 2):91-4. PubMed ID: 6119339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 12-sulfodehydroabietic acid monosodium salt (TA-2711), a new anti-ulcer agent, on gastric secretion and experimental ulcers in rats.
    Onoda Y; Magaribuchi T; Tamaki H
    Jpn J Pharmacol; 1989 Sep; 51(1):65-73. PubMed ID: 2509775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible mechanism of increase in gastric mucosal PGE2 and PGI2 generation induced by ecabet sodium, a novel gastroprotective agent.
    Kinoshita M; Tamaki H
    Dig Dis Sci; 1997 Jan; 42(1):83-90. PubMed ID: 9009120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori.
    Ito Y; Shibata K; Hongo A; Kinoshita M
    Eur J Pharmacol; 1998 Mar; 345(2):193-8. PubMed ID: 9600637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of peptic activity by sucralfate.
    Samloff IM; O'Dell C
    Am J Med; 1985 Aug; 79(2C):15-8. PubMed ID: 3929601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ecabet sodium (TA-2711), a new antiulcer agent, on gastrointestinal mucosal prostanoid production and morphology in rats.
    Kinoshita M; Iwasaki H; Yasoshima A; Tamaki H
    Biol Pharm Bull; 1993 Dec; 16(12):1220-5. PubMed ID: 8130770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a combination of ecabet sodium and cimetidine on experimentally induced gastric lesions and gastric mucosal resistance to ulcerogenic agents in rats.
    Kinoshita M; Noto T; Tamaki H
    Biol Pharm Bull; 1995 Feb; 18(2):223-6. PubMed ID: 7742788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ecabet sodium on experimentally induced reflux esophagitis.
    Omura N; Kashiwagi H; Chen G; Yano F; Suzuki Y; Aoki T
    J Gastroenterol; 2000; 35(7):504-9. PubMed ID: 10905357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of prostaglandins, nitric oxide and the capsaicin-sensitive sensory nerves in gastroprotection produced by ecabet sodium.
    Kinoshita M; Kume E; Tamaki H
    J Pharmacol Exp Ther; 1995 Oct; 275(1):494-501. PubMed ID: 7562591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients.
    Shimoyama T; Fukuda Y; Fukuda S; Munakata A; Yoshida Y; Shimoyama T
    J Gastroenterol; 1996 Nov; 31 Suppl 9():59-62. PubMed ID: 8959522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ecabet sodium, a novel gastroprotective agent, on mucin metabolism in rat gastric mucosa.
    Ichikawa T; Ishihara K; Hayashida H; Hiruma H; Saigenji K; Hotta K
    Dig Dis Sci; 2000 Mar; 45(3):606-13. PubMed ID: 10749340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori.
    Shibata K; Kasuga O; Yasoshima A; Matsushita T; Kawakami Y
    Jpn J Antibiot; 1997 Jun; 50(6):525-31. PubMed ID: 9258741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between gastroprotective effect of locally acting antiulcer agent ecabet sodium and its binding to gastric mucosa in rats. Comparison with sucralfate.
    Kinoshita M; Yamasaki K; Kokusenya Y; Tamaki H
    Dig Dis Sci; 1995 Mar; 40(3):661-7. PubMed ID: 7895562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells.
    Hayashi S; Sugiyama T; Yachi A; Yokota K; Hirai Y; Oguma K; Fujii N
    J Gastroenterol; 1997 Oct; 32(5):593-7. PubMed ID: 9349983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.